University of Glasgow (UGLA), UK
The Prostate Cancer Biology Group is located within the CRUK Beatson Institute, a centre of excellence core-funded by Cancer Research UK, which focuses on key aspects of cancer cell behaviour. The Institute has open plan laboratories and modern social spaces to maximise interaction between researchers. Its strengths lie in its cutting-edge technologies – with a particular focus on imaging, metabolomics and transgenic models of cancer – and its interactive environment that encourages a high degree of collaboration amongst its scientists. The Beatson is also a key partner in the CRUK Glasgow Centre, which aims to integrate Glasgow's considerable strengths in cancer research.
ESR 1 at UGLA will have opportunities to present talks and posters on their work at local seminars, national and international conferences. The University Graduate School monitors progress of all students. We have a credit system whereby students attend modular courses and must achieve a minimum number of credits prior to graduation. Besides their supervisors, each student is assigned two mentor/advisors with whom they meet with twice yearly to ensure good progress and address issues promptly. Award of PhD degree follows a successful valedictory seminar and thesis defence (internal and external examiner).
Cutting-edge infrastructure/facilities available: pre-clinical models, Poly-omics Facility, Drug discovery, Clinical resources.
University of Newcastle (UNEW), UK
The Urology Research Group is part of the Northern Institute for Cancer Research (NICR) at Newcastle University. The NICR is a multi-disciplinary research institute and houses a dedicated small molecule drug discovery unit closely linked to clinical trials unit. There are excellent core-funded facilities for proteomics, DNA analysis, cell sorting, animal models, bioinformatics and confocal/electron microscopy. Substantial links exist with SME and large Pharma, e.g. Newcastle-Astex Alliance. The Faculty Graduate School training program is fully compliant with the QAA Code of Practice for Postgraduate Research Programs, including a flexible approach to training. ESR2 will maintain an electronic record of their training as an ePortfolio.
Cutting-edge infrastructure/facilities available: Microscopy, Drug discovery, Proteomics/Sequencing facility, AR studies, ChIP-seq, stem cell isolation.
Queen's University Belfast (QUB), UK
The Prostate Cancer Research Group is based within one of four internationally recognised Research Centres, the Centre for Cancer Research and Cell Biology (CCRCB) within the School of Medicine, Dentistry and Biomedical Sciences. The cross-faculty, interdisciplinary Centre for Cancer Research and Cell Biology (CCRCB) is committed to the highest quality of research excellence. To achieve our mission, we are pursuing a premier series of research programmes in defined areas, combining innovative discovery science with clinical translational to achieve the best outcomes for cancer patients. In recognition of the international standing of CCRCB, the University has made, and continues to make, significant investment in both academic staff and infrastructure. CCRCB has over 200 staff, with 34 Principal Investigators, 60 Postdoctoral fellows and 65 postgraduate students from across the world working together in a new, purpose-built research facility. CCRCB offers training modules in Cancer Biology and Translational Cancer Medicine, as part of a training programme in Precision Cancer Medicine. Students can gain Credit Accumulation and Transfer Scheme (CATS) credits/European Credits Transfer System (ECTS) credits by taking these modules. Additional training is delivered through the Postgraduate Researcher Development Programme which offers comprehensive training, one to one support and skills development opportunities for research students at the University. The curriculum for ESR3 involves poster or oral presentations at national or international conferences, and the program concludes with a public lecture prior to a viva voce examination with an international opponent. CCRCB offers training in nucleic acid extraction and sequence capture, cell culture and sample handling. In addition there is access to additional training closely linked to the themes of the consortium. In particular CCRCB will provide local training in the quality control, alignment and scoring of next-generation sequencing data in conjunction with the Cancer Bioinformatics and Imaging group and supported by a number bioinformatics lecturers who are developing a range of workflows for deriv ing biomarker signatures from multi-omic data (e.g. PICan: An integromics framework for dynamic cancer biomarker discovery). Much of this training has also been formalised and accredited through an MSc in Bioinformatics and Computational Genomics and ESR Fellows are welcome to attend key components of this course.CCRCB also host a number of spinout and start-up biotech companies and also provides hybrid exposure to industry and academia.
Cutting-edge infrastructure/facilities available: ChIP-seq, bioinformatics, genomics, imaging, molecular pathology and biobanking, The Northern Ireland Cancer Trials Centre.
University of Turku (UTU), Finland
University of Turku (UTU)), the oldest university in Finland, has recently established the Turku Prostate Cancer Consortium (TCPP) incorporating the University Hospital Turku, Auria Biobank, and the Institute of Biomedicine. Core facilities, e.g. the Centre for Biotechnology (CBT) including Turku Bioimaging (www.bioimaging.fi) & the Finnish DNA Sequencing and Microarray Centre and the Proteomics Unit, and the National PET Centre are in place. The ESRs will enrol in one of the local graduate programs. They organise extensive, coordinated research training including courses, seminars and national and international symposia. ESR4 will present research results at local, national and international meetings and write 3-5 papers for their theses which they defend at a public examination.
Cutting-edge infrastructure/facilities available: Novel culture methods, GEMM, Omics technologies, Drug discovery, High content screening platforms, automated phenotypic image analyses and image processing software.
Erasmus MC (EMC), The Netherlands
Experimental Urology is embedded in the multi-disciplinary "Rotterdam Prostate Research Group". ESR5 will become a member of the Postgraduate School of Molecular Medicine, which facilitates all molecular/cell biology and complementary training and education at PhD and postdoc level. The ESR will be trained to be able to perform and develop animal experiments and become a principle investigator in initiating animal research. The Experimental Urology research group has weekly lab meetings and the ESR will have separate weekly consultations with his/her supervisors. The ESR will present his/her work regularly at lab meetings, internal EMC group meetings and the yearly Molecular Medicine day.
Cutting-edge infrastructure/facilities available: pre-clinical in vitro / in vivo PDX models, Clinical resources, Microscopy, Life imaging, High content
numares HEALTH (NUM), Germany
numares AG is an IVD system provider and IVD test manufacturer. Founded in 2004 as a spin-off from Biophysics Department at University of Regensburg, a highly reputed center of magnetic resonance in Chemistry and Biomedicine, numares has developed nuclear magnetic resonance (NMR) based metabolomic analysis to a point ready for routine clinical use certified by ISO13485 standards. The system provides simultaneous quantitative detection of organic metabolites by proprietary algorithms without need for separation steps in a single analytical step. The cutting edge nature of this system with its high analytical reproducibility and simplicity build the technological base for numares' world leading position in NMR-based clinical analytics with 20 successful installations of numares NMR instruments at US customer sites processing a 24/7 operation of several thousand samples/day. numares headquarters are in Regensburg (Germany), with subsidiaries in Boston (Mass. US) and Singapore.
Cutting-edge infrastructure/facilities available: Metabolomic methodologies, bioinformatics, large scale dataset available, extensive hands-on experience of the research & development team.
Biomedical Research Foundation Academy of Athens (BRFAA), Greece
The Biomedical Research Foundation of the Academy of Athens (BRFAA) is one of the major Institutes for Biomedical research in Greece. The BRFAA Proteomics Research Unit is equipped with multiple state-of the art proteomics technologies to be employed in iMODE-CKD, including systems for two-dimensional electrophoresis, liquid chromatography (HPLC, FPLC), preparative protein electrophoresis, spot pickers for automated spot excision, matrix assisted laser desorption-ionization time-of-flight mass spectrometer (MALDI-TOF/TOF) with imaging MS capabilities etc.
Cutting-edge infrastructure/facilities available: Proteomic methodologies, Informatics, Systems biology approach.
University of Tampere (UTA), Finland
ESR8 will be enrolled in the PhD-program (Tampere Graduate Program in Biomedicine & Biotechnology, TGPBB). TGPBB organizes training, which includes e.g. weekly seminars (presentations by external speakers), 2-3 theoretical seminars and/or lab courses per year, as well as an annual Research Day. The ESR will also participate in bioinformatic courses organized by UTA. A steering group, consisting supervisor (Dr. Visakorpi), and two external experts will be designated to the ESR. The steering group will follow the progress of the fellow's studies, and will meet at least once a year.
Cutting-edge infrastructure/facilities available: ChIP-seq, Transcriptomic analysis, Informatics, Clinical resources.
GenomeScan (SXS), The Netherlands
ESR9 will enrol in the local PhD-program organized by UGLA. A supervisor at UGLA will act as an internal supervisor to support the main supervisor at SXS. A credit system consisting of modular courses will be used. Besides their supervisors, each student will be assigned two mentors/advisors with whom they will meet twice yearly to ensure good progress and promptly address concerns. Award of PhD degree follows a successful valedictory seminar and thesis defence with an internal and external examiner.
ESR 11, a nine month appointment, will not be enrolled in a PhD programme but will nevertheless benefit from supervision from both SXS and UGLA.
Cutting-edge infrastructure/facilities available: Next generation sequencing analysis, Bio-informatics, Mathematical modelling.
ALMAC Diagnostics, UK
ESR10 will enrol in the regular PhD-program in the Center for Cancer Research and Cell Biology, Queens University Belfast. The student will receive an unrivalled training experience in cutting edge technology in a rich research environment between the University and Almac Diagnostics. New students at the University undertake an induction course, including all aspects of laboratory work, cancer medicine, Translational Science, and data analysis/ management.
Students also attend a series of lectures and master-classes from invited speakers who are leaders in their field. Journal clubs form part of the training programme and students have significant opportunities to develop their presentation skills through a series of Research and Educational Fora. The student will work under the supervision of Dr Nuala McCabe and Prof Richard Kennedy who have a wealth of experience in biomarker discovery.
Cutting-edge infrastructure/facilities available: Biomarker development through in silico analysis and preclinical modelling.
Hing Leung (Co-ordinator)
Professor of Urology and Surgical Oncology at the University of Glasgow
Skill set: Both clinical and laboratory trained. Active clinical practice in prostate cancer. Major expertise in aberrant signalling as driver events for prostate cancer. Instrumental in multiple drug discovery programs, with two having reached Phase I clinical evaluation. Extensive experience in supervising both clinical and basic science doctoral students.
Linda Rushworth (TransPot Scientific Programme Manager)
Post Doctoral Researcher at the University of Glasgow
Skill set: Laboratory trained with many years of experience and a wide skill set. Completed a PhD from the Beatson Institute in 2006, and worked as a Post Doctoral Researcher at the University of Dundee for 8 years. Returned to the Beatson Institute in 2015 to work as part of Professor Hing Leung's Prostate Cancer group. Previous experience of PhD student supervision.
Craig Robson (PI)
Professor of Molecular Urology at the University of Newcastle
Skill set: Trained molecular and cell biologist with experience in prokaryotic and eukaryotic model systems. Primary current areas of expertise in translational cancer research to identify biomarkers and novel protein targets for drug development in cancer. Longstanding commitment to training and supervising basic science and clinical PhD/MD students in translational cancer research.
Ian Mills (PI)
Associate Director for Postgraduate Studies, CCRCB at Queen's University Belfast
Skill set: Laboratory trained with both scientific and clinical backgrounds. Major expertise in transcriptional regulation and functional impacts on cellular trafficking and metabolism. Targets identified are further tested as biomarkers and therapeutics. Metabolic targeting as an adjunct/sensitizer to anti-androgens/chemotherapy. Prior experience of supervision within EU FP ITN networks.
Pirkko Härkönen (PI)
Professor at the University of Turku
Skill set: Research on hormone regulation and FGF signalling pathways in PC. Expertise in GEMMs and explant prostate cultures. Co-founder of 3 biotech companies, driving force in early drug discovery programs, with one accepted by FDA in 2013. Extensive experience in supervising MD (n=10) and MSc (n=11) students to achieve PhDs and postdoctoral fellows at UTU, Finland and at Lund University, Sweden.
Docent at the University of Turku
Skill set: Experienced in both applied and basic research, related to early stage drug discovery (high content and high throughput Screening). Development of cell- and tissue-based model systems, for target validation and drug chemosensitivity testing; in academic settings, public-private partnerships; or as contract research with the pharmaceutical industry. Supervising postdoctoral candiates, PhD and Masters' Students in Germany, USA, and Finland.
Wytske M. van Weerden (PI)
Associate Professor at Erasmus MC
Skill set: Biology trained. Focus on prostate cancer. Major expertise in PC disease modelling, (castration/chemo) resistance mechanisms, targeted imaging and therapy. Longstanding expertise in industry-driven projects and drug evaluation programs, extensive knowledge in supervising both medical and basic science students.
Eric Schiffer (PI)
Head of Clinical Development Dept. at numares HEALTH
Skill set: More than 10 years experience in industrial biomarker development, implementation, development of clinical tests, and regulatory issues, track record in clinical metabolomics and proteomics analysis and biomarker research, extensive knowledge in supervising both medical and basic science students and employees; strong leadership and project management experience.
Antonia Vlahou (PI)
Staff Research Scientist - Professor Level at the Biomedical Research Foundation of the Academy Of Athens
Skill set: Antonia Vlahou, Ph.D is group leader and co-Director of the Proteomics Research Unit, BRFAA. She received her BS from School of Biology, University of Athens, Greece and holds a Ph.D on cell biology from Baylor College of Medicine Houston USA. She has more than 10years experience on clinical proteomics and has played leading role in the development of standardized approaches in biomarker discovery. Among her distinctions is the Pfizer Scholar in Urology award and her role as the Chair of the Management Committee of the European Kidney and Urine Proteomics COST Action (www.eurokup.org; 2008-2012). As well as her role as PI in TransPot, Dr Vlahou has also been partner in the FP7 DECanBIO (2008-2012) and is currently partner in Marie Curie IAPP ProtoClin, and EID BCMolMed, and FP7 NEURINOX. She serves as the coordinator of the iMODE-CKD program.
Jerome (Makis) Zoidakis
Research Associate at the Biomedical Research Foundation of the Academy Of Athens
Skill set: Jerome (Makis) Zoidakis, PhD is a research associate at the proteomics laboratory of BRFAA. He studied Biology and Biochemistry at the University of Liege (Belgium) focusing on psychrophilic enzyme structure and function. He conducted research at UCLA as a PhD student studying the stability and catalytic properties of Phenylalanine Hydroxylase and other metalloenzymes. He has received numerous awards for his research and teaching accomplishments. Since 2008 he is a member of the proteomics laboratory of BRFAA. His research interests are biomarker discovery for prostate, bladder and cervical cancer. He is actively involved in teaching proteomics classes at the graduate level and he is in charge of training activities of the COST action CLINIMARK. In the context of TransPot, he will be the second supervisor of ESR7 and will mentor other ESRs who will do a secondment at the proteomics laboratory of BRFAA.
Tapio Visakorpi (PI)
Professor of Cancer Genetics at the University of Tampere
Skill set: Extensive experience of basic and translational cancer research in PC. Deep knowledge of genomics and ARmediated signalling. Supervised MSc, PhD and post-doctoral fellows. Involved in PhD thesis steering groups and organized courses for PhD students.
Bart Janssen (PI)
Innovation and Quality Manager at at GenomeScan
Skill set: Extensive experience of genetic and genomic research. Supervised MSc, PhD and post-doctoral fellows. Involved in PhD thesis steering groups and organized courses for PhD students, post doc fellows and clinical staff.
R&D Scientist at GenomeScan
Skill set: Extensive experience of genetic and genomic research.
Richard Kennedy (PI)
Medical Director of Almac Diagnostics at ALMAC Diagnostics
Skill set: Prof Kennedy holds the post of Professor of Medical Oncology, Queens University Belfast and, is Vice President and Medical Director of Almac Diagnostics. Prof Kennedy has a wealth of experience in the analysis of gene expression data for the discovery and development of prognostic and predictive biomarkers. Importantly these assays will impact clinical care. The DDRD assay is a predictor for chemotherapy in breast cancer, the AADX assay will be delivered as a prognostic clinical test for ovarian cancer and a further test for colon cancer, COLDX is entering clinical practice in 2017 through collaboration with Helomics (a US-based biomarker company). Prof Kennedy is also Belfast lead for Experimental Cancer Medicine Centre (ECMC), a UK wide initiative, whose goal is to drive the development of new therapies through Phase I/II clinical trials. Prof Kennedy has successfully supervised 8 PhDs involving both scientists and clinical research fellows.
Head of Research, Almac Diagnostics and Honorary Lecturer Queens University Belfast
Skill set: Dr Nuala McCabe graduated from Queen's University Belfast in 1997 with a Honours Degree in Biomedical Science. She then carried out her Ph.D. training in the Department of Oncology (Queen's University Belfast) under the supervision of Prof. Paul Harkin. Following this, she then worked as a post-doctoral researcher for 5 years with Prof. Alan Ashworth in the Breakthrough Breast Cancer Research Centre (Institute of Cancer Research, London). During this time she was the involved in the identification of PARP1 inhibitors for the treatment of BRCA-associated breast and ovarian cancers, whichare now approved by the EMA for BRCA associated cisplatin sensitive ovarian cancer.
Dr McCabe joined Almac Diagnostics as Team Leader of Internal Research and has progressed to Head of Research for the Internal Products Division. Within this role she has gained 8 years industrial experience in drug target identification and biomarker discovery. Dr McCabe has a Honorary position at Queen's University Belfast and runs a team of both industrial and academic staff with a focus on the discovery and validation of biomarkers for clinical trials. Dr McCabe has successfully supervised a number of clinical and scientific PHD students (4), Masters students (3) and undergraduate students (4) within this role.
Dr McCabe's work has led to a number of significant publications including Nature, Cancer Research, Cancer Cell, Oncogene, Oncotarget, Nucleic Acid Research and Journal of the National Cancer Institute.
Rafael Sánchez Martínez
ESR at the University of Glasgow
I am from Murcia, in southeast Spain. It was there at University of Murcia where I obtained my Bachelor's degree in Biochemistry. Then I moved to Valladolid, where I studied a Master's degree in Biomedical Research, taught by the University if Valladolid and the Institute of Molecular Biology and Genetics (IBGM). During my masters I worked on lipids related to inflammation. I studied the effect of free fatty acids on the development of an inflammatory phenotype in monocyte/macrophague cells.
In the TransPot network, I expect to be working in the characterisation and validation of molecular targets related to the development of prostate cancer and specially, castration resistant prostate cancer. In the lab, I enjoy reading all I can about my research field and then try to come up with interesting experiments. I like to have the widest possible knowledge of interesting techniques and experiments so I can know what tools to use in my own research.
In my spare time, I like to watch movies and series, as well as read books, especially those I think will leave a mark in me. When I am not being that pretentious, I enjoy cooking, exercising and playing some videogames with my friends from Spain.
ESR at the University of Newcastle
My name is Parmveer Singh and I am from Canada. I completed my undergraduate degree at the University of Toronto, majoring in Human Biology as well as Biological Anthropology. In my final years of my undergraduate degree, I was involved diabetes-related research in two different labs. After exposure to scientific research, I had decided that it was a career path I wanted to follow. I then pursued a Master of Science degree at the University of Alberta, specializing in Molecular Biology and Genetics. My project focused of the genetic aspects neural tube defects. While I am still refining my research interests, I am particularly fascinated by the use of molecular biology techniques and gene manipulation for the development of disease therapies.
My time as a TransPot ESR will be spent at Newcastle University. I will be studying prostate stem cell biology and organogenesis in order to efficiently produce prostate organoids for further research and to better understand the development of prostate cancer. I am hoping that TransPot will assist me in becoming a more productive and independent researcher while also meeting and training with other researchers with similar interests and goals.
During my spare time, I enjoy staying active with sports such as basketball and boxing. I also like to travel and explore the world around me and experience new cultures and cuisines.
ESR at the Queen's University of Belfast
I come from a place called Kashmir which lies in the north of India. I have a family background of Medical Researchers, Medical Professionals and Teachers. I completed my undergrad (Biochemistry honors; 3 years) from Kashmir University with 1st Division and then pursued my Master's degree in Biotechnology from Jamia Hamdard University, New Delhi in 1st Division with Distinction, (CGPA Score: 9.13). During the last 6 months of my degree, I opted to work in cancer biology laboratory for 6 months and successfully defended my MSc. thesis entitled "Effect of Macrotyloma Uniflorum against Cervical Cancer" before a committee of Science Faculty. After successfully completing my Master's degree I received "SURE Fellowship from Hormel Institute, University of Minnesota" where I worked in a Prostate Cancer Laboratory in the section of Molecular Chemoprevention and Therapeutics at The Hormel Institute. I have an abstract in the Conference proceeding of AACR:
Saleem M, Ganaie A, Maqbool R, Beigh FH, Umbreen S, Dulynova K, Konety BR. Developing novel inhibitors of S100A4 for neuroendocrine (NE) and metastatic prostate cancer: systematic testing using relevant models and drug development techniques. Annual Meeting of American Association for Cancer Research, April 1-5, 2017, Washington, D.C. USA
I aspire to become a molecular biologist with an interest in the research fields related to human diseases especially prostate cancer. My focus has always been medical sciences. There is continuity of my interest right from Bachelor's degree till now in the field of medical science research and my interest in this field shall remain forever!
The project within the TransPot EU Consortium will allow me to further develop the approaches (ChIP seq, ATAC seq and FAIRE seq) through access to a range of novel prostate cancer models and clinical samples and in conjunction with other partners who will be generating complementary omics and drug response datasets within the time period of this project. In the course of the project, I will also undertake three research secondments each of two months with three partner institutions where I will obtain additional practical experience of patient- based prostate cancer models and cross-platform data analysis and exposure to bioinformatics in a non- academic context. One of my secondments is the industrial secondment where I will gain exposure to the corporate sector of the field.
My long-term goal is to become a productive researcher in the field of biomedical sciences, publish high-impact papers in top-notch journals, learn grantsmanship, write Grant Proposals and file patents.
ESR at the University of Turku
I have graduated with the following degrees: Post graduate diploma in Cellular and Molecular Diagnostics from The Oxford college of science, Bangalore University, India in October 2016. Bachelor of Engineering in Biotechnology from BMS college of engineering, Visvesvaraya Technological University, India in June 2014.
I have worked as a research fellow at high throughput screening/high content imaging facility, Centre for Cellular and Molecular Platforms, National Centre for Biological Sciences, Bangalore, India from Apr 2016 to May 2017 (Fellowship awarded by Department of Biotechnology, Government of India). Also, I have gained experience in molecular biology techniques at Triesta sciences, Diagnostic and R&D laboratory, HCG cancer hospital, Bangalore, India from Dec 2014 to June 2015 (Fellowship awarded by Biotech Industrial Training Program (BITP), Government of India).
As a student of science, I enjoy the challenge of optimizing, analyzing and implementation of newer concepts, protocols and technologies as a part of my research. I also like being a part of various scientific workshops and talks. Furthermore, the collaboration between academia and industries is a factor of the Marie Sklodowska Curie ITN network which appeals to my way of learning as this justifies the application perspective of theoretical knowledge.
My research interest briefly includes exploring novel diagnostic and therapeutic targets of cancer with advanced in-vitro, in-vivo models and research technologies that are more realistic and reliable compared to existing models.
I am eager to explore the possibility of developing and working on organotypic 3D-tissue models and explant cultures of prostate cancer including castration resistant prostate cancer (CRPC). Herewith, I aim to explore the analysis of human prostate cancer specimens and their hormone and paracrine (FGF/FGFR-mediated) regulation, targeted therapy particularly against prostate cancer, screening of compounds to identify hits against prostate cancer. Furthermore, I would like to have developed excellent scientific acumen, good networking skills and work with scientists from across Europe through collaborations.
I enjoy socializing, cooking, reading and practicing yoga.
ESR at the University of Tampere
I am Mina Sattari, graduate of veterinary medicine from Urmia University, Urmia, Iran.
During my veterinary course, I was interested in Biochemistry and Molecular Biology so I joined a scientific group in the department of biochemistry focusing on molecular biology fields. As a veterinarian, I am so interested in molecular biology research which kind of means I am going to switch research fields rather than medical care or treatment of the animal. Meanwhile, after graduation, I gained expertise in the field of bacterial cultures, protein expression, and purification, food analysis chemistry, microbiology and routines in veterinary medicine. Besides, I have been trained in techniques such as cell culture, molecular methods including PCR, Real-time PCR, etc.
My hope is to learn much more professional knowledge in the field of Molecular Biology of Prostate Cancer. I will avail myself of the ample academic activities to exchange and to learn from leading specialists, and to develop new perspectives. In this way, I hope to achieve so innovative research results and produce several high-quality research papers. I expect that the research-intensive Ph.D. training there will help me become well prepared for careers in Molecular Biology of Prostate Cancer research.
My hobbies and interests include socializing with friends and family, reading novels, watching TV and traveling.
ESR at Almac Diagnostics
My name is Cathal McKinney and I am from Republic of Ireland. I received my Bachelor's degree in Genetics from the Smurfit Institute of Genetics of Trinity College Dublin. I became interested in computational and statistical analysis during my studies and decided to further explore this field of research by securing a place in the master's program of Bioinformatics and Computational Genomics at Queen's University Belfast. As a Master's student, I researched the prognostic ability of hypoxia gene signatures in oesophageal adenocarcinoma. I am interested in personalised medicine, specifically disease stratification through biomarker discovery and assay development.
Within the TransPot training network, I will be working on the project "Consensus subtyping in prostate cancer" under the supervision of Dr. Nuala McCabe of Almac Diagnostics and Dr. Jaine Blayney of the Centre for Cancer Research and Cell Biology. The main aim of this project is to identify novel molecular subtypes of prostate cancer, to investigate the biological and clinical characteristics of the identified subgroups and to determine their prognostic and predictive utility. Additionally, I will be validating pre-existing assays developed by Almac in prostate cancer including the DDRD and MEK/EMT assays. By working as part of the TransPot training network and Almac Diagnostics, I will have the opportunity to perform research that has the potential to have a profound impact on the treatment of prostate cancer. Outside of academia, my hobbies include running in the mornings, watching good movies, and exploring Belfast at the weekends.
Prostate Cancer UK
Prostate Cancer UK leads the fight against prostate cancer. We fund ground-breaking research, drive improvements in treatment, and fight injustice in care. Now we’ve set ourselves the toughest challenge yet: to stop prostate cancer being a killer. Through shifting the science to focus on radical improvements in diagnosis, treatment, prevention and support, we can make prostate cancer a disease the next generation of men need not fear.
Biography: Iain Frame is currently Director of Research at Prostate Cancer UK He is a member of the Executive Team, reporting directly to the Chief Executive. With senior colleagues, Iain leads Prostate Cancer UK in key areas of business including, strategic planning, budget management, staff development and in ensuring the successful delivery of the charity's bold and ambitious strategy Ten Years to Tame Prostate Cancer. Iain also supports and advises the Board of Trustees on internal and external issues pertaining to medical research. Iain is a strong advocate of getting results by developing partnerships and using innovative approaches to support the research community to deliver results to benefit men with prostate cancer.
Iain was previously at Diabetes UK where he held the post of Research Director for five years, during which time he took forward its funding of high quality, internationally acclaimed studies and worked with the fundraising teams to help almost double the organisation's research spend. Iain started in the world of charitable research funding with the Wellcome Trust, following many years actively involved in research as a parasitologist.
Helsinki University Central Hospital
Helsinki University medical campus has top facilities for contemporary translational prostate cancer research. Helsinki University Hospital, Dept. of Urology and the Dept. of Pathology (Haartman Institute) are situated next to the Institute for Molecular Medicine Finland (FIMM), a research institute with Nordic EMBL partnership status. FIMM is a modern research institute with high-throughput tissue and cellular arrays, multispectral imaging and virtual microscope platforms developed in-house. FIMM technology centre offers sequencing and drug screening facilities as well as expertise in bioinformatics. Close collaboration with urologist forms an advanced environment for translational prostate cancer research and training. University of Helsinki is among 100 best universities in the world annually in the Times Higher Education World University Rankings' in clinical, pre-clinical and health research. In addition to comprehensive retrospective registries and tissue collections, the collaborative integration in Transpot offers world-leading environment for prospective integrated biobanking, with Helsinki Biobank as a provider of clinical prostate cancer materials.
Biography: Dr. Tuomas Mirtti, (MD, PhD, Adjunct Professor) is a consulting pathologist and senior research scientist at Helsinki University and FIMM. He has supervised 6 MD/M.Sc theses and is currently supervising 6MD, PhD theses. He is conducting research and clinical work on urological cancers, mainly prostate cancer, with 15 years' experience. The areas of expertise are urological, GI and breast pathology and research is conducted in a global network, especially with prostate cancer researchers. He has published 50 peer-reviewed scientific articles. The special interests are tissue biomarkers, survival and treatment effect prediction and personalised medicine in urological cancers.
European Association of Urology
ESUR aims to promote basic and clinical research in the field of urology and related areas. We act as a platform for researchers in different disciplines, in order to improve the coordination of experimental research.
The EAU Section for Urological Research was founded more than 25 years ago by a small group of scientists as the European Society for Urological Oncology and Endocrinology (ESUOE). The society was renamed as the European Society for Urological Research. During the 24th Annual EAU Congress in Stockholm in 2009, ESUR became an EAU Section, and joined the EAU Section Office. Today, ESUR meetings provide top-quality content in the field of research. Speakers are selected on the basis of their contributions, scientific standing, and innovative approaches. ESUR has an ever-increasing number of participants and the meeting participants are drawn to the meetings' scientific content. ESUR also contributes to the Annual EAU Congress.
Most of our researchers are engaged in oncology research. However, ESUR also welcomes scientists in other areas. The section covers a number of subspecialty topics like non-malignant diseases and emerging fields such as tissue engineering. Both researchers with PhD and MD degree participate in ESUR activities and are represented in the Board.
Biography: Prof. Dr. Kerstin Junker is a senior physician and Head of the Department of clinical-experimental research at the Clinic of Urology, Homburg. She is a speaker of the German kidney cancer network and a member of the Interdisciplinary Task Force Renal Cell Tumors of the German Cancer Association. In addition, since 2009 she has been the Chair of the Section of Urological Research of the European Association of Urology.
Carver Wilde Communications
Carver Wilde is an integrated PR and marketing consultancy which focuses on clinical diagnostics, medical devices, life sciences, FMCG and sustainable resources.
Relevant Biomedical Clients and Partners include:
- Beckman Coulter Life Sciences.
- Philips Digital Pathology/Philips Handheld Diagnostics.
- Stago UK.
- Danaher business units - with a special focus on clinical flow cytometry and in vitro diagnostics.
- European Randomized Study of Screening for Prostate Cancer (ERSPC).
- Pro- NEST: Associate Partner and Supervisory board member.
- Translational Research Network for Prostate Cancer.
Biography: Jennie Wilde is a specialist in the global B2B communications and marketing of life sciences/biotechnology and clinical diagnostics solutions. As a writer she excels in taking complex content and creating clarity of message. A graduate in English, Latin and Biology, Jennie has formal marketing training and degree‐level study in philosophy. She is an individual member of the UK's Public Relations and Communications Association (PRCA) and the Chartered Institute of Public Relations (CIPR).
Before establishing Carver Wilde, she spent several years at global PR consultancy Burson‐Marsteller, managing campaigns for international brands and organisations spanning healthcare, FMCG and legal issues. Jennie started her professional life as a newspaper and TV news & current affairs journalist and subeditor. She wrote widely on medical issues. Her TV work included current affairs documentaries on German industrial best practice. She carried out film assignments for UK government to promote UK expertise overseas. This included work for the Foreign Office and the Ministry of Defence for which she has signed the Official Secrets Act.
Cancer Research Technology
At Cancer Research Technology Discovery Laboratories (CRT DL, part of CR UK) we aim to translate basic research findings to therapies for cancer patients. We act as a bridge between large and small Pharma companies and academics, bringing the two together to exploit ideas and inventions for the benefit of cancer patients. We do this by offering small molecule drug discovery and alliance management expertise in large scale academic-pharma collaborations with the express goal of getting new therapies into patient studies. We rely heavily on partnerships with our clinical and academic contacts to enable the best teams of scientists to work with Pharma.
Biography: Tim Hammonds has a degree in Pharmacy and a PhD in pharmaceutical chemistry and microbiology from the University of Nottingham. After 5 years enzymology research at the Biochemistry Department at the University of Leicester, Tim joined CRT DL in 1999. During his time there he has built and run an assay development, protein production and an HTS department. Now Deputy Director of Discovery Tim spends his time managing all aspects of translational drug discovery; from the operational aspects of the early drug discovery process, right through to the negotiation and management of multi-site academic/industry drug discovery alliances.
Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., Barbier, M., Blom, S., Arundkar, S. C., Selvam, I., Osswald, A., Stein, Y., Gruenewald, S., Brito C., van Weerden, W., Rotter, V., Boghaert, E., Oren, M., Sommergruber, W., Chong Y., de Hoogt, R. and Graeser, R. (2016). Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery, 6, 28951. http://dx.doi.org/10.1038/srep28951
Hickman, J. A., Graeser, R., de Hoogt, R., Vidic, S., Brito, C., Gutekunst, M., van der Kuip, H. and IMI PREDECT consortium (2014), Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo. Biotechnology Journal, 9: 1115–1128. doi:10.1002/biot.201300492
de Morrée, E., van Soest, R., Aghai, A., de Ridder, C., de Bruijn, P., Ghobadi Moghaddam-Helmantel, I., Burger, H., Mathijssen, R., Wiemer, E., de Wit, R. and van Weerden, W. (2016), Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. Prostate, 76: 927–936. doi:10.1002/pros.23182
S de Morrée, E., Böttcher, R., van Soest, R., Aghai, A., de Ridder, C., Gibson, A., … Weerden, W. (2016). Loss of SLCO1B3 drives taxane resistance in prostate cancer. British journal of cancer. https://doi.org/10.1038/bjc.2016.251
Davies, E. J., Dong, M., Gutekunst, M., Närhi, K., van Zoggel, H. J. A. A., Blom, S., … Hickman, J. A. (2015). Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices, 5, 17187. http://dx.doi.org/10.1038/srep17187
Moad M, Hannezo E, Buczacki SJ, Wilson L, El-Sherif A, Sims D, Pickard R, Wright NA, Williamson SC, Turnbull DM, Taylor RW, Greaves L, Robson CN, Simons BD, Heer R. Multipotent Basal Stem Cells, Maintained in Localized Proximal Niches, Support Directed Long-Ranging Epithelial Flows in Human Prostates. Cell Rep. 2017 Aug 15;20(7):1609-1622. doi: 10.1016/j.celrep.2017.07.061.
Urbanucci, A. et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep 19, 2045-2059, doi:10.1016/j.celrep.2017.05.049 (2017).
Barfeld, S. J. et al. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. EBioMedicine 18, 83-93, doi:10.1016/j.ebiom.2017.04.006 (2017).
Barfeld, S. J. & Mills, I. G. Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing. Methods Mol Biol 1443, 119-137, doi:10.1007/978-1-4939-3724-0_8 (2016).
Barfeld, S. J. et al. Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget 6, 12587-12602, doi:10.18632/oncotarget.3494 (2015).
Mills, I. G. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 14, 187-198, doi:10.1038/nrc3678 (2014).
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 721746